was successfully added to your cart.
Cannabis LegislationElixinol NewsIndustry EventsIndustry News

Elixinol CEO and Co-Founder Paul Benhaim Speaks at First-Ever Asian Hemp Summit

By February 1, 2019 No Comments
Paul Benhaim attends first ever Asian Hemp Summit

by Chris Husong

Elixinol CEO and co-founder Paul Benhaim continued to make international hemp history at the first-ever Asian Hemp Summit February 1-2, 2019, in Kathmandu, Nepal.

Paul Benhaim Asian Hemp Summit Kathmandu, Nepal

Paul Benhaim speaks at first Asian Hemp Summit, Feb. 1-2, 2019, in Nepal

The objective of the summit was to bring global hemp industry players together to discuss the rapidly-growing industrial hemp industry in Asia. Sessions took a deep dive into the industrial hemp sectors in China, Japan, India, South Korea, Thailand, and Mongolia.

Topics discussed included:

  • Hemp CBD extract
  • Harvesting and cultivating industrial hemp
  • Hemp foods and drinks
  • Cosmetic, health and beauty product made with hemp
  • Investing in the Asian industrial hemp market
  • Hemp accessories, clothing, and fabrics
  • Variety of construction materials made from hemp
  • Farm equipment for hemp cultivation
  • Hemp biocomposites
  • Types of hemp processing tech, including extraction methods
  • Discussions around importing and exporting hemp
  • Hemp research and development
Paul Benhaim with Nepalese Minister for Home Affairs

Elixinol CEO Paul Benhaim and the Nepalese Minister for Home Affairs – Asian Hemp Summit, 2019

Featured guests at the event represented Nepal, Japan, Germany, Australia, France, Czech Republic, Mongolia, and more.

Elixinol, which continues to outperform other ASX-listed companies with a 150% increase in stocks since early 2018, was among a powerhouse group of hemp industry leaders represented at the summit.

WHO Makes New CBD Recommendations

Today, the World Health Organization (WHO) Expert Committee on Drug Dependence (ECDD) released new recommendations regarding CBD products made from industrial hemp. WHO now recommends that CBD products containing less than 0.2% THC be completely removed from international drug control conventions and 100% excluded from the controlled substances schedule.

The WHO report continued, “The Committee recommended that a footnote be added to Schedule I of the 1961 Single Convention on Narcotic Drugs to read: ‘Preparations containing predominantly cannabidiol and not more than 0.2% of delta-9-tetrahydrocannabinol are not under international control.'”

This is an incredibly important worldwide distinction for full-spectrum CBD extract made from industrial hemp. While the 2018 Farm Bill opened wider access to hemp CBD extracts in the United States, hemp regulations still vary on an international level.

Hemp CBD is non-addictive and non-intoxicating; in other words, it doesn’t get you “high.” If the WHO’s recommendations are followed, we could see hemp CBD become more accessible than ever–on a worldwide level.